The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Weight loss jabs, known as GLP-1 receptor agonists, work by reducing food cravings. In October, the MHRA told health ...

A major new study has highlighted significant health risks associated with popular weight loss injections such as Ozempic, ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Recent research reveals that weight-loss injections reduce the risk of 42 health conditions in people with diabetes, ...

The new drug, amycretin, similar to the company's blockbuster weight-loss and diabetes drugs Wegovy ... The company tested the once-weekly injection on 125 people for up to 36 weeks with ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Weight loss injections can play an important role in efforts to tackle obesity when prescribed as part of a carefully managed treatment programme for patients who are most in need of support.